Agoracom Blog Home

Posts Tagged ‘MMJ’

INTERVIEW: Tetra Bio-Pharma $TBP.ca Discusses Clinical Study for Smoked #Marijuana #CBD #MMJ $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:21 AM on Friday, November 17th, 2017

Tetra Bio-Pharma is no ordinary Medical Cannabis company. As a true Cannabis Bio-Pharma company, the company is the FIRST and ONLY pharmaceutical company in clinical trials for smoked marijuana, which is currently set to enter the valuable Phase 3 part of the trial.

AGORACOM Sat Down With President, Bernard Fortier To Discuss The Following:

1. How conducting clinical trials is massive differentiator from other companies.
2. The duration of Phase 3
3. The size of the market that will be available upon successful completion of Phase 3
4. How a successful Phase 3 can help solve the opioid crisis
5. Why the Company believes its’ inhalation device will generate $1.5M in revenue for Fiscal 2018
6. The Company’s distribution partnership with Aphria
7. Where the Medical Cannabis industry will be within 5 years

ThreeD Capital Inc. $IDK.ca Acquires Securities of Global Cannabis Applications Corp. $APP.ca $PNP.ca $ZC.ca

Posted by AGORACOM-JC at 10:13 AM on Thursday, November 16th, 2017

Threed capital

  • Acquired ownership and control of an aggregate of 2,000,000 common shares and 2,000,000 common share purchase warrants of Global Cannabis Applications Corp. 
  • Represented approximately 3.7% of all issued and outstanding common shares of Global Cannabis

TORONTO, Nov. 16, 2017 – ThreeD Capital Inc. ( “ThreeD”) (CSE:IDK) is pleased to announce that it has acquired ownership and control of an aggregate of 2,000,000 common shares (the “Subject Shares”) and 2,000,000 common share purchase warrants (the “Subject Warrants” and together with the Subject Shares, the “Subject Units”) of Global Cannabis Applications Corp. (“Global Cannabis”) on November 15, 2017.  The Subject Units represented approximately 3.7% of all issued and outstanding common shares of Global Cannabis as of November 15, 2017 immediately following the transaction described above (or approximately 7.2% on a partially diluted basis, assuming exercise of the Subject Warrants only), resulting in a corresponding increase in the percentage of shares held by ThreeD and its Joint Actor as a result of the transaction.

Immediately before the transaction described above, ThreeD and the Joint Actor held an aggregate of 2,850,000 common shares of the Company (the “Pre-Closing Shares”), representing approximately 5.5% of the issued and outstanding common shares of the Company.  Of this total, ThreeD held an aggregate of 1,000,000 of the Pre-Closing Shares (representing approximately 1.9% of the issued and outstanding common shares of the Company), and the Joint Actor held an aggregate of 1,850,000 of the Pre-Closing Shares (representing approximately 3.6% of the issued and outstanding common shares of the Company).

Immediately following the transaction described above, ThreeD and the Joint Actor held an aggregate of 4,850,000 common shares (the “Post-Closing Shares”) and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 2,000,000 common shares of the Company (the “Post-Closing Convertible Securities”), representing approximately 9.0% of the issued and outstanding common shares of the Company (or approximately 12.3% assuming exercise of such Post-Closing Convertible Securities only).  Of this total, ThreeD held an aggregate of 3,000,000 of the Post-Closing Shares and 2,000,000 of the Post-Closing Convertible Securities (representing approximately 5.6% of the issued and outstanding common shares of the Company, or approximately 9.0% assuming exercise of such Post-Closing Convertible Securities only), and the Joint Actor held an aggregate of 1,850,000 of the Post-Closing Shares and nil of the Post-Closing Convertible Securities (representing approximately 3.4% of the issued and outstanding common shares of the Company).

The Subject Units were acquired in a private placement and not through the facilities of any stock exchange.  The holdings of securities of Global Cannabis by ThreeD and the Joint Actor are managed for investment purposes, and ThreeD and the Joint Actor could increase or decrease their investments in Global Cannabis at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor. The aggregate consideration payable for the Subject Units was $200,000, or $0.10 per Subject Unit.

The trade was effected in reliance upon the exemption contained in Section 2.3 of National Instrument 45-106 on the basis that each of ThreeD and the Joint Actor is an “accredited investor” as defined herein.

About ThreeD Capital Inc.

ThreeD Capital Inc. is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources, Artificial Intelligence and Blockchain sectors.

ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s network in order to earn increases to the Company’s equity stake.

For further information:
Gerry Feldman, CPA, CA
Chief Financial Officer and Corporate Secretary
Feldman@threedcap.com
Phone: 416-606-7655

Tetra Bio-Pharma Inc. $TBP.ca Rx Princeps(TM) Now Available for Patients through Licensed Producer Partner Aphria $APH.ca $AERO $CBDS $CGRW $GBLX

Posted by AGORACOM-JC at 8:23 AM on Thursday, November 16th, 2017

Logo tetrabiopharma rgb web

  • Announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc.

OTTAWA, ONTARIO–(Nov. 16, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. (“Aphria”) under Access to Cannabis for Medical Purposes Regulations (ACMPR).

Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now entering this lucrative market and plans on progressively grabbing a significant share of it over the next two years. Mr Fortier, CEO of Tetra, stated last week “We are expecting to generate around $1.5 million in sales, in fiscal 2018 in our initial launch. Through our promotion and education efforts in Quebec, New Brunswick and part of Ontario, we estimate that over eight thousand patients will start using Rx Princeps™ under prescription from their doctors over in the next twelve months.”

Rx Princeps™ is a new option for doctors who want to prescribe medical cannabis. Prescribing Rx Princeps™ with the Rx Princeps™ inhalation device enables their patients to optimize the benefits of medical cannabis through the intake of a fixed dose of product, thereby ensuring consistency of treatment with a standardized high-quality product.

Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada. As a result, Aphria’s products are in line with the strict quality standards Tetra is establishing for the medical community and its patients.

200,000 patients are already registered under the ACMPR program and around 1.5 million adults in Canada suffer from chronic pain and are considered non-responders to opioids; medical cannabis could be a new therapeutic choice for those patients but physicians need bioavailability and safety data to prescribe medical cannabis with confidence. According to Health Canada, less than 3,000 physicians actually prescribe cannabis to their patients. Tetra is committed to provide them rigorous safety and bioavailability data. Tetra has begun educating pain clinics and the medical profession across Canada on Rx Princeps™, including its advantages for patients.

In Quebec, Tetra is working closely with Sante Cannabis in order to educate patients and support them in their medical journey with cannabis. Sante Cannabis is the first cannabinoid clinic and medical marijuana resource centre in Quebec.

About Rx Princeps™:

Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001. Patients who want to purchase Rx Princeps™ in Canada need a prescription from their physicians and to register with Licensed Producer Aphria.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com

Namaste $N.ca Provides Corporate Update on #Cannmart and Namaste MD #MMJ #Marijuana

Posted by AGORACOM-JC at 8:19 AM on Thursday, November 16th, 2017

Nlogo

  • Provides an update on progress with its wholly owned subsidiary, Cannmart Inc.
  • Updated Access to Cannabis for Medical Purposes Regulations application has been submitted to Health Canada, the CannMart facility is now under construction
  • Company expects a six to eight-week time-frame for completion, pending any delays

VANCOUVER, British Columbia, Nov. 16, 2017 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ)(OTCMKTS:NXTTF) is pleased to provide an update on progress with its wholly owned subsidiary, Cannmart Inc. (“CannMart”). Management is excited to announce that the updated Access to Cannabis for Medical Purposes Regulations (“ACMPR”) application has been submitted to Health Canada, the CannMart facility is now under construction and the Company expects a six to eight-week time-frame for completion, pending any delays. Namaste’s design goals for the CannMart facility will facilitate the seamless distribution of a wide variety of medicinal cannabis products, which have been sourced both domestically and internationally. Namaste believes that once construction is complete, this state of the art facility will serve as the backbone in servicing Namaste’s impressive and growing database of Canadian medical cannabis consumers.

Further to Namaste’s press release dated November 14, 2017, the application for NamasteMD, the Company’s innovative telemedicine smart-phone app, has been submitted to both the Apple Store and Google for approval, and will available on both IOS and Android devices once approval is received. Additionally, Namaste is pleased to announce that it has engaged multiple doctors and nurse practitioners who will be trained to provide consultations on the NamasteMD app and issue medical documents to Namaste’s patients. NamasteMD has been designed to provide a simple process for patients to connect with a doctor or nurse practitioner through a virtual consultation from the comfort of their home or office. NamasteMD incorporates proprietary identity and age verification technology that will provide high confidence verification for all patients.  Patients who complete their consultation and receive a medical document through NamasteMD may then connect to CannMart’s online portal where they can purchase a wide range of medicinal cannabis products. By utilizing Namaste’s innovative technology of machine-learning algorithms and integrating CannMart on the NamasteMD platform, Namaste strongly believes that it will soon become Canada’s leading online retailer for medicinal cannabis.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “These are extremely exciting times for Namaste as we move forward and implement many new and innovative initiatives. We are very excited about the progress of both CannMart and NamasteMD and believe the next few months will be transformational for the Company. I would like to thank all shareholders for their continued support and in helping Namaste reach these important milestones.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors
“Sean Dollinger”
Chief Executive Officer
+1 (786) 389 9771
Email: Sean@NamasteTechnologies.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Compound in #cannabis could ease #asthma #CBD #MMJ $MCOA $TBP.ca

Posted by AGORACOM-JC at 12:58 PM on Thursday, November 9th, 2017

 

Hebrew University Prof. Raphael Mechoulam, known as the “father” of the medical cannabis industry, will lead a team investigating the benefits of non-psychoactive cannabis components for treating asthma and other respiratory conditions.

In 1964, Mechoulam, was the first scientist to successfully isolate the THC component in cannabis. He was then a young researcher at Israel’s Weizmann Institute of Science.

Of the 140 cannabinoid molecules in the cannabis plant, the two main components are THC (the psychoactive component) and CBD, which has anti-inflammatory properties. CBD is the focus of much of Israel’s burgeoning medical cannabis research on diabetes, heart disease, autism, fracture healing and inflammatory bowel disease.

Mechoulam will conduct studies on CBD and asthma together with Prof. Francesca Levi-Schaffer at the Hebrew University’s recently established Multidisciplinary Center on Cannabis Research. The research has been commissioned by CIITECH, a UK-Israeli biotech startup headed by Clifton Flack, who cofounded iCAN-Israel Cannabis. The latter is beginning clinical testing on a cannabis formulation for insomnia.

Allergic diseases including asthma, allergic rhinitis, atopic dermatitis and food allergies affect approximately 20 percent of the global population.

Mechoulam’s asthma research aim is to identify “a possible inhibitory effect of a derivative of cannabidiol (CBD) on allergic airway inflammation.”—More…

Source: http://canadafreepress.com/article/compound-in-cannabis-could-ease-asthma

Tetra Bio-Pharma $TBP.ca Goes After the #Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with #SantéCannabis

Posted by AGORACOM-JC at 8:29 AM on Thursday, October 26th, 2017

Tbp large new

  • Announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market
  • vision is to develop an evidence-based approach similar to that of any other prescription drug, thereby allowing physicians and pharmacists to prescribe and dispense these medicines to patients in need

OTTAWA, ONTARIO–(Oct. 26, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.

Last year Tetra launched several drug development programs to commercialize cannabis-based prescription drugs making it one of the world leaders in cannabinoid pharmaceuticals. Tetra’s vision is to develop an evidence-based approach similar to that of any other prescription drug, thereby allowing physicians and pharmacists to prescribe and dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are hesitant to support the use of these products because of the lack of data supporting its medical use; even though healthcare professionals have to offer the best available care to patients, they also need to ensure that the treatment dispensed by pharmacists does no harm.

Since 2015, the Canadian cannabis oil market has grown from below 600 kg in the first quarter (Jan-Mar) of 2016 to over 6000 kg in the same first quarter of 2017, and it is expected that this market will continue to show significant growth according to a July 26, 2017 report by Eight Capital. Based on an estimated average sales price of $75-100 per 60 ml for cannabis oil, the 2017 global cannabis oil sales in Canada could exceed 30 million dollars.

According to Tetra’s Chief Executive Officer (CEO), Bernard Fortier,” Tetra is in a good position to penetrate this market. We have been preparing for months how to differentiate ourselves within this market while maintaining our corporate vision of an evidence-based approach. The cannabis oil market will be no different for Tetra. The corporation is dedicated to providing evidence and supporting physicians and other healthcare professionals while making cannabis accessible to their patients. We are on target to initiate our sales strategy by March 2018 to carve out a solid position within the Canadian market. We expect to generate revenues in the cannabis oil market in 2018 and we will grow these revenues as physicians become aware of our scientific approach and patient care programs. Based on a conservative market penetration estimate, we are targeting to grow our share of the cannabis oil business to over 1 million in revenues by 2019.”

Furthermore, Tetra is announcing that it is supporting a post-marketing study (phase 4 clinical trial) of the use of cannabis oil in the treatment of chronic pain. This trial is driven by the medical experts of Santé Cannabis and will provide much needed safety and efficacy data in this patient population. Tetra will be supporting Santé Cannabis in this important endeavor with its internal regulatory and scientific team. Data generated by this study will help Tetra’s medical team in educating physicians on the potential of cannabis oils to treat patients suffering from chronic pain. Once completed, this trial will allow Tetra to penetrate even further into the cannabis oil market making it one of the key players as it continues to grow its share of this over 30-million-plus dollar market.

Tetra’s scientific team is also supporting the sales strategy by initiating a safety and pharmacokinetic study in healthy volunteers (phase 1 clinical trial) to characterize the safe use of these cannabis oil medicines in humans. Combined with the study in patients suffering from chronic pain, Tetra will have a solid and credible position in the medical cannabis oil market. Dr. Chamberland, Tetra’s Chief Scientific Officer (CSO), commented that” physicians are concerned about the potential side effects and well-being of patients using cannabis oil. It is this type of data that continues to allow Tetra to differentiate itself in the medical cannabis market as we become leader in the field. Over and over, physicians and pharmacists welcome the pharmaceutical approach used by Tetra as it is a proven model for bringing safe and efficacious therapies to patients. Patients are expecting their healthcare professionals to treat cannabis like a medicine and help ensure that they safely consume these products. This expectation from patients will soon be fulfilled by Tetra’s strategic approach to patient care.”.

From a business point of view, these studies are part of the sales and marketing strategy required to effectively penetrate a physician-pharmacist product market. The outcome of these studies will also support Tetra’s overall drug development strategy and it is expected that this will allow Tetra to reduce the overall time-to-market for a number of its cannabis-based prescription drugs. The company will also use this data to create novel new products that will allow Tetra to further increase its revenues in the cannabis oil market.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
anne-sophie.courtois@tetrabiopharma.com
(514) 360-8040 Ext. 210
www.tetrabiopharma.com

FEATURE: Tetra Bio-Pharma $TBP.ca – Only Pharma Company To Have Clinical Studies for Smoked #Marijuana #MMJ #CBD

Posted by AGORACOM-JC at 11:38 AM on Tuesday, October 24th, 2017

WHY TETRA BIO-PHARMA?

 

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected

Tetra Bio-Pharma $TBP.ca Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

Posted by AGORACOM-JC at 8:07 AM on Thursday, October 19th, 2017

Tbp large new

  • Announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).
  • Will be responsible for the medical information of Rx Princeps™ and will be educating the medical community about the benefits of this controlled and standardized blend of medical cannabis

OTTAWA, ONTARIO–(Oct. 19, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).

Dr. Jourdain will be responsible for the medical information of Rx Princeps™ and will be educating the medical community about the benefits of this controlled and standardized blend of medical cannabis. Dr. Jourdain has extensive training and knowledge in pharmacology and neuroscience and is a critical addition to the Tetra team. An important part of his role will be to support the sales of Rx Princeps™ through New Brunswick and the Maritimes, as well as in Quebec, by presenting the safety, pharmacokinetic, and pharmacodynamic data gathered in Tetra’s Phase 1 clinical trial of PPP001.

“The addition of Dr. Jourdain demonstrates our strategic intention to position Tetra Bio-Pharma as the leader in the medical cannabis market. Bringing an individual with the level of scientific knowledge and expertise of Dr. Jourdain shows our organization’s commitment to the medical community; they can continue to count on Tetra Bio-Pharma as a credible and professional source of information for their practice and their patients. We are looking forward to further developing relationships with opinion leaders in the field as we continue to advance our clinical program and work on bringing new drug alternatives for patients and their treating healthcare professionals.” states Dr. Guy Chamberland, Chief Scientific Officer of Tetra.

Tetra also reveals today its new logo and corporate image, thereby aligning its corporate image with its medical strategy. The evolution of The Company’s image highlights Tetra’s objective to be the reference for the medical community in prescribed cannabinoids’ safety, efficacy, and quality. Tetra is focused on bringing to the ACMPR market the highest quality medical cannabis; the Company remains committed to receive the first drug approval from Health Canada’s Therapeutic Products Directorate for a medical cannabis drug.

About RxPrinceps:

Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001.

Rx Princeps™ will soon be available across Canada, through our partner Aphria’s customer service, for patients who have a prescription from their physicians.

About Dr. Vincent Jourdain, Ph.D.:

Dr. V. Jourdain, Ph.D. is a graduate from the pharmacy program at Laval University in Quebec City, where he specialized in neurological disorders. He completed his postdoctoral training at the Feinstein Institute for Medical Research in New York. He used brain imaging to study metabolic and neurovascular changes in Parkinson’s disease and pharmacologically-induced side effects. Dr. Jourdain possesses a broad, yet specialized, knowledge in Neurology and accumulated close to 10 years of experience in basic and clinical research. He published over 15 peer-review publications and won several awards and scholarships.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
anne-sophie.courtois@tetrabiopharma.com
(514) 360-8040 Ext. 210

Tetra Bio-Pharma $TBP.ca Signs Agreement with Partner Aphria $APH.ca to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

Posted by AGORACOM-JC at 8:12 AM on Wednesday, October 18th, 2017

Tbp large new

  • Will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR)
  • Signed a distribution agreement with its trusted partner Aphria to sell Rx Princeps™, its unique blend of dried medical cannabis used in its PPP0001 clinical trials

OTTAWA, ONTARIO- (Oct. 18, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx Princeps™, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the coming weeks.

Rx Princeps™ will be a new option for doctors who want to prescribe medical cannabis, while ensuring that their patients will receive a consistent and high-quality product. Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada, thereby complying with the quality standards Tetra wants to bring to the medical community and its patients.

Rx Princeps™ will be a new therapeutic option not only for the 19% of adults who suffer from chronic pain in Canada, but also for the more than 200,000 patients already registered under the ACMPR program. Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now prepared to enter this lucrative market.

“Our objective is to position ourselves as the reference for the medical community in the prescription of medical cannabis, and gain our growing share of that market in the years to come. We believe that we are bringing additional value to patients, physicians and other key healthcare professionals involved in treating at-need patients. We are ready to launch our first medical product, and we couldn’t be more pleased to do it with a partner such as Aphria, which has demonstrated their commitment to our vision of offering a medical product of the highest quality. Our team is dedicated to make this part of our business a very successful one, bringing value to our investors in the process. Being able to generate revenue to support our operations is an important step for Tetra Bio-Pharma,” says Bernard Fortier, CEO of Tetra Bio-Pharma.

About Rx Princeps:

Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001.

Rx Princeps™ will be available across Canada, through Aphria’s customer service, for patients who have a prescription from their physicians.

About Aphria:

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information about Aphria, please contact:
Nina Godard – Edelman
416-455-6324
nina.godard@edelman.com

Vic Neufeld, President & CEO
1-844-427-4742

For further information about Tetra Bio-Pharma
and Rx Princeps(TM), please contact Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com

Global Hemp Group $CHG.ca and Marijuana Company of America $MCOA to Enter Joint Venture Agreement with Space Cowboys’ Colorado Farm

Posted by AGORACOM-JC at 11:18 AM on Tuesday, October 10th, 2017

15233 mcoa

  • Marijuana Company of America Inc.  and Global Hemp Group  announce that they have jointly entered into a letter of intent with Space Cowboys, Inc. or the purposes of forming a joint venture
  • Space Cowboys is an existing fully licensed and compliant hemp-derived cannabinoid producer in Colorado

Escondido, California–(October 10, 2017) – Marijuana Company of America Inc. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and Global Hemp Group (CSE: GHG) (FSE: GHG) (OTC Pink: GBHPF), (collectively the “Companies“), are pleased to announce that they have jointly entered into a letter of intent with Space Cowboys, Inc. (“Space Cowboys“) for the purposes of forming a joint venture (the “Joint Venture“). Space Cowboys is an existing fully licensed and compliant hemp-derived cannabinoid producer in Colorado.

Pursuant to the terms of the letter of intent and subject to the Companies obtaining sufficient financing, the Companies will invest US$2.5 Million in exchange for a 25% equity interest in Space Cowboys. The investment funds will be used to expand Space Cowboys’ cultivation operation.

Space Cowboys is in its fourth year of operation and is in full compliance with Colorado state law and the Colorado Department of Agriculture. The business consists of both indoor and outdoor cultivation of highly concentrated CBD hemp on properties located in Longmont and Loveland, Colorado. Space Cowboys’ current hemp crops will be harvested in the latter part of October and prepared for extraction of the high-value cannabinoids.

In addition to the potential revenue streams generated from Space Cowboys’ ongoing high cannabinoid hemp production, this Joint Venture will provide the opportunity to be a part of a legal operation with the extensive knowledge and experience required to cultivate and process industrial hemp into raw cannabinoids. For MCOA, it will also provide a consistent cannabinoid supply from a known source and trusted partner for its hempSMART™ product line. This will also enable Global Hemp Group to develop its Hemp Agro-Industrial Zone concept.

“MCOA has always been interested in developing hemp farms and processing here in the United States. By initiating this Joint Venture, the Company will accomplish this objective along with securing its supply chain of raw cannabinoids. It is an important step in the continued development of the hempSMART brand, which distributes a hemp-based Cannabinoid product line,” said CEO, Donald Steinberg.

The transaction is subject to a number of conditions, including but not limited to, completion of satisfactory due diligence, entry into a definitive agreement and receipt of any necessary regulatory approvals. There is no assurance such conditions will be met or that the Companies will be able to secure the financing necessary to complete the transaction on acceptable terms or at all.

About Space Cowboys

Space Cowboys operates hemp farms in the state of Colorado for the primary purpose of Cannabinoid production. Space Cowboys’ operations are in full compliance with Colorado state law and the Colorado Department of Agriculture.

About Global Hemp Group Inc.

Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp and cannabis, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and establish a greater collective valuation.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Email Contact